CFIUS influence may have prompted Momenta's restructuring

As biotech’s concerns over trade tensions between the U.S. and China intensify, details have come to light of a biopharma deal derailed by stricter CFIUS regulations. The scuttled deal may have contributed to Momenta's decision to slash half of its workforce last year.

Steve Dickman first reported in Forbes on Friday that Momenta President and CEO Craig Wheeler told the publication that a proposed spinout of part of its business to a syndicate of China-based investors collapsed last year over concerns about the Committee on Foreign Investment in the United States. Momenta could not be reached for comment...